Topic:

Clinical Trials

Latest Headlines

Latest Headlines

MD Anderson Cancer Center adds to its growing life science universe with Tesaro deal

Texas is adding more eggs to its incubator as cancer biopharma Tesaro has inked a deal with UT's MD Anderson Cancer Center for new immuno-oncology targets.

Rho seeks 30 new hires after bumper year

Private CRO Rho is looking for a swath of new staffers after a strong 2015 that saw it gain new contracts and returning clients.

Quintiles named 'best CRO in Asia' again

The world's biggest CRO, Quintiles, had a good Easter as it was named as the best CRO in Asia for fourth time in 6 years.

Under pressure, XenoPort sells U.S. rights of failed psoriasis pill to Dr. Reddy's

Dr. Reddy's Laboratories has signed a $490 million drug licensing deal with California's XenoPort as the struggling biotech looks to shed its R&D; ahead of a rumored sale of the company.  

UPDATED: Alder rockets up as promising migraine data heats up a frenzied race for CGRP drug approval

Alder Therapeutics posted positive--and competitive--data for their Phase IIb study of a new CGRP drug for migraine, keeping it in the hectic race aimed at coming up with the first new drug approval in the crowded space.

Californian biotechs Forge Therapeutics and Active Motif sign epigenetics research deal

The metalloproteins specialist Forge Therapeutics and Active Motif, which develops tools to help "turn off" certain genes, have penned a new deal in epigenetic research.

GE-backed Neuronetics' device may offer a long-term alternative to drugs for depression: Study

Devices to treat depression haven't had any big market breakthroughs. But key to achieving that is to show that they are a viable alternative to drug therapies--and that their impact can show a sustainable treatment benefit.

The 'Uber for experiments' group Science Exchange raises $25M

Science Exchange--which runs an outsourcing business service for biopharma and smaller life science groups--has raised $25 million in a new Series B funding round as it looks to broaden its offering after a strong 2015.

PTC Therapeutics to cull its ranks after FDA spurns Duchenne drug

PTC Therapeutics is to axe nearly a fifth of its workforce in the summer, just weeks after the FDA knocked back its application for the muscular dystrophy drug Translarna.

Quintiles, Mitsui and investors pay toward a new $866M development fund

The world's biggest CRO Quintiles and a number of international investors have come together to create a new fund aimed at lightening the cost burden of pharma drug development.